ZLZheng Li

Zheng Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zheng Li has a total of 139 co-authors. Here are the top co-authors by number of shared publications:

  • Andreas Sjödin

    Centers for Disease Control and Prevention, National Center for Environmental Health, Atlanta, USA

    5 shared publications
  • Lovisa C. Romanoff

    Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of STD Prevention, Atlanta, USA

    4 shared publications
  • Andreas Sjödin

    Division of Laboratory Sciences, Centers for Disease Control and Prevention, Atlanta, GA, 30341, United States

    3 shared publications
  • Angela Ragin-Wilson

    Agency for Toxic Substances and Disease Registry

    3 shared publications
  • Debra A. Trinidad

    Centers for Disease Control and Prevention, National Center for Environmental Health, Division of Laboratory Sciences, Atlanta, USA

    3 shared publications
  • Erin N. Pittman

    Centers for Disease Control and Prevention, National Center for Environmental Health, Division of Laboratory Sciences, Atlanta, USA

    3 shared publications

Latest Publications

  • Open Access

    Urinary 3-Phenoxybenzoic Acid in U.S. Children and Adolescents: Temporal and Demographic Patterns in NHANES, 1999–2002 and 2007–2018

    by Siddhi Desai, Maria Ospina, Po-Yung Cheng, Shuaikang Hou, Hoormat Qureshi, Mohammad Shoeb, Zheng Li, Christopher Reh, Patricia Ruiz

    Background: Pyrethroid pesticides are widely used, and children may experience exposure through multiple nonoccupational pathways. Urinary 3-phenoxybenzoic acid (3-PBA) is a commonly used biomarker of recent pyrethroid exposure. Methods: In this repeated cross-sectional analysis, we analyzed U.S. National Health and Nutrition Examination Survey (NHANES) data for participants aged 3–19 years from 1999–2002 and 2007–2018. Urinary 3-PBA data were unavailable for 2003–2006. Descriptive statistics for urinary 3-PBA concentrations were creatinine-corrected and estimated by age group and survey cycle. For regression analyses, urinary 3-PBA concentrations were not creatinine-corrected; instead, log-transformed urinary 3-PBA was modeled with urinary creatinine included as a covariate, along with survey cycle, age group, sex, race/ethnicity, and poverty–income ratio (PIR). Analyses incorporated subsample weights with SUDAAN software. Results: Among 7415 U.S. children and adolescents, the overall creatinine-corrected geometric mean urinary 3-PBA concentrations were 0.31 [95% CI: 0.25, 0.39] and 0.93 [0.80, 1.08] µg/g creatinine for survey cycles 1999–2000 and 2017–2018, respectively. Concentrations were higher in younger children than in older children. Urinary 3-PBA concentrations were generally higher in later survey cycles. Adjusted models showed that urinary 3-PBA concentrations were higher among younger children and children from lower-income households and were lower among non-Hispanic Black, Mexican American, and Other race/ethnicity groups compared with non-Hispanic White children. Survey cycle was positively associated with urinary 3-PBA in the 1999–2002 and 2007–2014 model but was not statistically significant in the 2015–2018 model. Sex was not consistently associated with urinary 3-PBA across the two analytic periods. Conclusions: Recent pyrethroid exposure, as reflected by urinary 3-PBA, was widespread and socially patterned among U.S. children and adolescents. Urinary 3-PBA varied by age group, survey cycle, race/ethnicity, and poverty–income ratio. These findings should be interpreted as exposure surveillance data rather than evidence of specific health effects. Ongoing biomonitoring, source-focused research, and studies with repeated exposure assessments would help to better understand the factors influencing pyrethroid exposure and its public health significance in children.

  • Lead and cancer: a narrative review and risk of bias assessment (2003–2020)

    by Carol Cusack, Tara C. Serio, Noelle B. Henderson, Kathryn B. Egan, Zheng Li, Teresa W. Wang

    Lead exposure may contribute to harmful human health effects, but evidence of its carcinogenicity is limited. The International Agency for Research on Cancer (IARC) in 2006 classified lead as “probably carcinogenic” (Group 2A), based on limited evidence in humans and sufficient evidence in animals. To further synthesize evidence on lead’s carcinogenicity, this review included a literature search and risk of bias assessment of 43 peer-reviewed epidemiological studies on lead exposure and cancer outcomes published between 2003 and 2020. Using the National Toxicology Program’s Office of Health Assessment and Translation Risk of Bias approach, 13 Tier One studies (primarily low risk) and 30 Tier Two studies (low and high risk) were identified. These studies characterized lead exposure through biologic media (i.e., blood, urine, tissues, hair, nails), and/or work histories, and evaluated cancers of the biliary tract, brain and central nervous system, breast, digestive tract, head and neck, blood, mesothelium, reproductive organs, respiratory tract, skin, thyroid, and urinary tract. Notably, breast, thyroid, and head and neck cancers were not previously included in the IARC 2006 monograph. Across all site-specific cancers examined, at least one study reported an association with lead exposure except for skin cancer. Respiratory tract cancers had the most epidemiologic studies showing positive associations with lead exposure. Study limitations were commonly tied to risk of bias for confounding, exposure characterization, and outcome assessments. Taken together, future studies would benefit from robust experimental designs with thorough adjustments for confounders, large diverse populations, and standardized exposure assessments particularly for cancers with limited data.

  • Open Access

    Building Capacity Nationwide on Environmental Health and Protecting Communities From Harmful Chemical Exposures

    by Zheng Li, Alan Yarbrough, Angela Ragin-Wilson, Christopher Reh

    This column provides an overview of the Agency for Toxic Substances and Disease Registry’s key capacity development activities. The activities are organized into four major categories that target a different group of partners: environmental health professionals, healthcare professionals, state health departments, and communities.


  • Open Access

    The Contribution of Declines in Blood Lead Levels to Reductions in Blood Pressure Levels: Longitudinal Evidence in the Strong Heart Family Study

    by Wil Lieberman‐Cribbin, Zheng Li, Michael Lewin, Patricia Ruiz, Jeffery M. Jarrett, Shelley A. Cole, Allison Kupsco, Marcia O'LEary, Gernot Pichler, Daichi Shimbo, et al.

    Background: Chronic lead exposure is associated with both subclinical and clinical cardiovascular disease. We evaluated whether declines in blood lead were associated with changes in systolic and diastolic blood pressure in adult American Indian participants from the SHFS (Strong Heart Family Study). Methods and Results: Lead in whole blood was measured in 285 SHFS participants in 1997 to 1999 and 2006 to 2009. Blood pressure and measures of cardiac geometry and function were obtained in 2001 to 2003 and 2006 to 2009. We used generalized estimating equations to evaluate the association of declines in blood lead with changes in blood pressure; cardiac function and geometry measures were considered secondary. Mean blood lead was 2.04 μg/dL at baseline. After ≈10 years, mean decline in blood lead was 0.67 μg/dL. In fully adjusted models, the mean difference in systolic blood pressure comparing the highest to lowest tertile of decline (>0.91 versus <0.27 μg/dL) in blood lead was −7.08 mm Hg (95% CI, −13.16 to −1.00). A significant nonlinear association between declines in blood lead and declines in systolic blood pressure was detected, with significant linear associations where blood lead decline was 0.1 μg/dL or higher. Declines in blood lead were nonsignificantly associated with declines in diastolic blood pressure and significantly associated with declines in interventricular septum thickness. Conclusions: Declines in blood lead levels in American Indian adults, even when small (0.1–1.0 μg/dL), were associated with reductions in systolic blood pressure. These findings suggest the need to further study the cardiovascular impacts of reducing lead exposures and the importance of lead exposure prevention.


  • Domains of Excellence: A CDC Framework for Developing High-Quality, Impact-Driven Public Health Science Publications

    by Erin M. Parker, Bao-Ping Zhu, Zheng Li, Richard W. Puddy, Megan A. Jd Kelly, Colleen DrPH Scott, Ana Penman-Aguilar, Mahider A. Mekonnen, James W. Stephens

    Context: The Centers for Disease Control and Prevention (CDC) has a long history of using high-quality science to drive public health action that has improved the health, safety, and well-being of people in the United States and globally. To ensure scientific quality, manuscripts authored by CDC staff are required to undergo an internal review and approval process known as clearance. During 2022, CDC launched a scientific clearance transformation initiative to improve the efficiency of the clearance process while ensuring scientific quality. Program: As part of the scientific clearance transformation initiative, a group of senior scientists across CDC developed a framework called the Domains of Excellence for High-Quality Publications (DOE framework). The framework includes 7 areas (“domains”) that authors can consider for developing high-quality and impactful scientific manuscripts: Clarity, Scientific Rigor, Public Health Relevance, Policy Content, Ethical Standards, Collaboration, and Health Equity. Each domain includes multiple quality elements, highlighting specific key considerations within. Implementation: CDC scientists are expected to use the DOE framework when conceptualizing, developing, revising, and reviewing scientific products to support collaboration and to ensure the quality and impact of their scientific manuscripts. Discussion: The DOE framework sets expectations for a consistent standard for scientific manuscripts across CDC and promotes collaboration among authors, partners, and other subject matter experts. Many aspects have broad applicability to the public health field at large and might be relevant for others developing high-quality manuscripts in public health science. The framework can serve as a useful reference document for CDC authors and others in the public health community as they prepare scientific manuscripts for publication and dissemination.


    • 1 November 2022
      • Vol. 85  (4) , 40-42

    Public Health Assessment Site Tool and Affiliated Applications: A Key Resource for Evaluating the Health Impact of Community Exposure to Hazardous Chemicals

    by Tonia Burk, David Mellard, Gregory V. Ulirsch, Zheng Li

    As part of our continued effort to highlight innovative approaches to improve the health and environment of communities, the Journal is pleased to publish regular columns from the Agency for Toxic Substances and Disease Registry (ATSDR) at the Centers for Disease Control and Prevention (CDC). ATSDR serves the public by using the best science, taking responsive public health actions, and providing trusted health information to prevent harmful exposures and diseases related to toxic substances. The purpose of this column is to inform readers of ATSDR’s activities and initiatives to better understand the relationship between exposure to hazardous substances in the environment, its impact on human health, and how to protect public health.

  • Blood cadmium, lead, manganese, mercury, and selenium levels in American Indian populations: The Strong Heart Study

    by Zheng Li, Michael Lewin, Patricia Ruiz, Anne E. Nigra, Noelle B. Henderson, Jeffery M. Jarrett, Cynthia Ward, Jianhui Zhu, Jason G. Umans, Marcia O'LEary, et al.


  • Open Access

    Social Vulnerability and Rurality Associated With Higher Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection–Induced Seroprevalence: A Nationwide Blood Donor Study—United States, July 2020–June 2021

    by Zheng Li, Brian Lewis, Kevin Berney, Elaine Hallisey, Austin M Williams, Ari Whiteman, Luis O Rivera-González, Kristie E N Clarke, Heather B Clayton, Terry Tincher, et al.

    Background: Most studies on health disparities during the coronavirus disease 2019 (COVID-19) pandemic focused on reported cases and deaths, which are influenced by testing availability and access to care. This study aimed to examine severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody seroprevalence in the United States and its associations with race/ethnicity, rurality, and social vulnerability over time. Methods: This repeated cross-sectional study used data from blood donations in 50 states and Washington, DC, from July 2020 through June 2021. Donor zip codes were matched to counties and linked with Social Vulnerability Index (SVI) and urban-rural classification. SARS-CoV-2 antibody seroprevalences induced by infection and infection-vaccination combined were estimated. Association of infection-induced seropositivity with demographics, rurality, SVI, and its 4 themes were quantified using multivariate regression models. Results: Weighted seroprevalence differed significantly by race/ethnicity and rurality, and increased with increasing social vulnerability. During the study period, infection-induced seroprevalence increased from 1.6% to 27.2% and 3.7% to 20.0% in rural and urban counties, respectively, while rural counties had lower combined infection- and vaccination-induced seroprevalence (80.0% vs 88.1%) in June 2021. Infection-induced seropositivity was associated with being Hispanic, non-Hispanic Black, and living in rural or more socially vulnerable counties, after adjusting for demographic and geographic covariates. Conclusions: The findings demonstrated increasing SARS-CoV-2 seroprevalence in the United States across all geographic, demographic, and social sectors. The study illustrated disparities by race-ethnicity, rurality, and social vulnerability. The findings identified areas for targeted vaccination strategies and can inform efforts to reduce inequities and prepare for future outbreaks.


  • Open Access

    Countries with delayed COVID-19 introduction – characteristics, drivers, gaps, and opportunities

    by Zheng Li, Cynthia Jones, Girum S. Ejigu, Nisha George, Amanda L. Geller, Gregory C. Chang, Alys Adamski, Ledor S. Igboh, Rebecca D. Merrill, Philip Ricks, et al.

    Background: Three months after the first reported cases, COVID-19 had spread to nearly 90% of World Health Organization (WHO) member states and only 24 countries had not reported cases as of 30 March 2020. This analysis aimed to 1) assess characteristics, capability to detect and monitor COVID-19, and disease control measures in these 24 countries, 2) understand potential factors for the reported delayed COVID-19 introduction, and 3) identify gaps and opportunities for outbreak preparedness, particularly in low and middle-income countries (LMICs). We collected and analyzed publicly available information on country characteristics, COVID-19 testing, influenza surveillance, border measures, and preparedness activities in these countries. We also assessed the association between the temporal spread of COVID-19 in all countries with reported cases with globalization indicator and geographic location. Results: Temporal spreading of COVID-19 was strongly associated with countries’ globalization indicator and geographic location. Most of the 24 countries with delayed COVID-19 introduction were LMICs; 88% were small island or landlocked developing countries. As of 30 March 2020, only 38% of these countries reported in-country COVID-19 testing capability, and 71% reported conducting influenza surveillance during the past year. All had implemented two or more border measures, (e.g., travel restrictions and border closures) and multiple preparedness activities (e.g., national preparedness plans and school closing). Conclusions: Limited testing capacity suggests that most of the 24 delayed countries may have lacked the capability to detect and identify cases early through sentinel and case-based surveillance. Low global connectedness, geographic isolation, and border measures were common among these countries and may have contributed to the delayed introduction of COVID-19 into these countries. This paper contributes to identifying opportunities for pandemic preparedness, such as increasing disease detection, surveillance, and international collaborations. As the global situation continues to evolve, it is essential for countries to improve and prioritize their capacities to rapidly prevent, detect, and respond, not only for COVID-19, but also for future outbreaks.